

Nobumichi Tanaka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2032464/publications.pdf>

Version: 2024-02-01

177
papers

2,394
citations

279798

23
h-index

330143

37
g-index

188
all docs

188
docs citations

188
times ranked

3223
citing authors

#	ARTICLE	IF	CITATIONS
1	CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer. <i>Neoplasia</i> , 2016, 18, 636-646.	5.3	161
2	Collagen type IV alpha 1 (COL4A1) and collagen type XIII alpha 1 (COL13A1) produced in cancer cells promote tumor budding at the invasion front in human urothelial carcinoma of the bladder. <i>Oncotarget</i> , 2017, 8, 36099-36114.	1.8	76
3	Regulatory T Cells and Tumor-Associated Macrophages in the Tumor Microenvironment in Non-Muscle Invasive Bladder Cancer Treated with Intravesical Bacille Calmette-Guérin: A Long-Term Follow-Up Study of a Japanese Cohort. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2186.	4.1	71
4	Clinical impact of postoperative loss in psoas major muscle and nutrition index after radical cystectomy for patients with urothelial carcinoma of the bladder. <i>BMC Cancer</i> , 2017, 17, 237.	2.6	68
5	Integrative Assessment of Pretreatment Inflammation-, Nutrition-, and Muscle-Based Prognostic Markers in Patients with Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy. <i>Oncology</i> , 2017, 93, 259-269.	1.9	56
6	Prediction of postoperative renal function by preoperative serum creatinine level and three-dimensional diagnostic image reconstruction in patients with renal cell carcinoma. <i>Urology</i> , 2004, 64, 904-908.	1.0	52
7	Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer. <i>BMC Urology</i> , 2014, 14, 33.	1.4	49
8	Mycoplasma genitalium Infection and Chronic Inflammation in Human Prostate Cancer: Detection Using Prostatectomy and Needle Biopsy Specimens. <i>Cells</i> , 2019, 8, 212.	4.1	46
9	Neutrophil-to-lymphocyte ratio as a detection marker of tumor recurrence in patients with muscle-invasive bladder cancer after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 257.e11-257.e17.	1.6	44
10	Immunohistochemical Analysis of Inflammatory Cells in Benign and Precancerous Lesions and Carcinoma of the Prostate. <i>Pathobiology</i> , 2013, 80, 119-126.	3.8	43
11	Exploration of risk factors predicting outcomes for primary T1 high-grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: Long-term follow-up experience at a single institute. <i>International Journal of Urology</i> , 2015, 22, 541-547.	1.0	43
12	Syndecan-1 up-regulates microRNA-331-3p and mediates epithelial-to-mesenchymal transition in prostate cancer. <i>Molecular Carcinogenesis</i> , 2016, 55, 1378-1386.	2.7	39
13	Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab. <i>Diagnostics</i> , 2020, 10, 310.	2.6	38
14	Diagnostic and prognostic role of urinary collagens in primary human bladder cancer. <i>Cancer Science</i> , 2017, 108, 2221-2228.	3.9	36
15	Urinary and Rectal Toxicity Profiles After Permanent Iodine-125 Implant Brachytherapy in Japanese Men: Nationwide J-POPS Multi-Institutional Prospective Cohort Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 141-149.	0.8	35
16	Preoperative predictive factors focused on inflammation-, nutrition-, and muscle-status in patients with upper urinary tract urothelial carcinoma undergoing nephroureterectomy. <i>International Journal of Clinical Oncology</i> , 2019, 24, 533-545.	2.2	33
17	The Effects of Androgen Deprivation Therapy on Lipid Metabolism and Body Composition in Japanese Patients with Prostate Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 577-581.	1.3	31
18	Bone Scan Can Be Spared in Asymptomatic Prostate Cancer Patients with PSA of ≤ 20 ng/ml and Gleason Score of ≤ 6 at the Initial Stage of Diagnosis. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 1209-1213.	1.3	31

#	ARTICLE	IF	CITATIONS
19	Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy. <i>Radiation Oncology</i> , 2013, 8, 25.	2.7	31
20	Non-ischemic Nephron-sparing Surgery for Small Renal Cell Carcinoma: Complete Tumor Enucleation Using a Microwave Tissue Coagulator. <i>Japanese Journal of Clinical Oncology</i> , 2002, 32, 95-102.	1.3	29
21	Variations in International Prostate Symptom Scores, Uroflowmetric Parameters, and Prostate Volume After 125I Permanent Brachytherapy for Localized Prostate Cancer. <i>Urology</i> , 2009, 74, 407-411.	1.0	29
22	Trends of the Primary Therapy for Patients with Prostate Cancer in Nara Uro-oncological Research Group (NUORG): A Comparison Between the CaPSURE Data and the NUORG Data. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 588-592.	1.3	28
23	Diagnostic approach for cancer cells in urine sediments by 5-aminolevulinic acid-based photodynamic detection in bladder cancer. <i>Cancer Science</i> , 2014, 105, 616-622.	3.9	28
24	Correlation of Immune Cells and Cytokines in the Tumor Microenvironment with Elevated Neutrophil-To-Lymphocyte Ratio in Blood: An Analysis of Muscle-Invasive Bladder Cancer. <i>Cancer Investigation</i> , 2018, 36, 395-405.	1.3	28
25	5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma. <i>Oncology Letters</i> , 2012, 3, 1195-1202.	1.8	25
26	Prostate diseases and microbiome in the prostate, gut, and urine. <i>Prostate International</i> , 2022, 10, 96-107.	2.3	25
27	Expression of ferrochelatase has a strong correlation in protoporphyrin IX accumulation with photodynamic detection of bladder cancer. <i>Photodiagnosis and Photodynamic Therapy</i> , 2016, 13, 225-232.	2.6	23
28	Protoporphyrin IX induced by 5-aminolevulinic acid in bladder cancer cells in voided urine can be extracorporeally quantified using a spectrophotometer. <i>Photodiagnosis and Photodynamic Therapy</i> , 2015, 12, 282-288.	2.6	22
29	Predictive factors of rectal toxicity after permanent iodine-125 seed implantation: Prospective cohort study in 2339 patients. <i>Brachytherapy</i> , 2016, 15, 736-745.	0.5	22
30	NACC1, as a Target of MicroRNA-331-3p, Regulates Cell Proliferation in Urothelial Carcinoma Cells. <i>Cancers</i> , 2018, 10, 347.	3.7	22
31	The biochemical recurrence-free rate in patients who underwent prostate low-dose-rate brachytherapy, using two different definitions. <i>Radiation Oncology</i> , 2014, 9, 107.	2.7	21
32	Review by urological pathologists improves the accuracy of Gleason grading by general pathologists. <i>BMC Urology</i> , 2015, 15, 70.	1.4	21
33	Tadalafil, a phosphodiesterase type 5 inhibitor, improves bladder blood supply and restores the initial phase of lower urinary tract dysfunction in diabetic rats. <i>Neurourology and Urodynamics</i> , 2018, 37, 666-672.	1.5	21
34	Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival. <i>International Journal of Clinical Oncology</i> , 2018, 23, 1148-1159.	2.2	21
35	Dual benefit of supplementary oral 5-aminolevulinic acid to pelvic radiotherapy in a syngenic prostate cancer model. <i>Prostate</i> , 2019, 79, 340-351.	2.3	21
36	Gamma-Klotho exhibits multiple roles in tumor growth of human bladder cancer. <i>Oncotarget</i> , 2018, 9, 19508-19524.	1.8	21

#	ARTICLE	IF	CITATIONS
37	Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil -. <i>Radiation Oncology</i> , 2014, 9, 302.	2.7	20
38	Clinical significance of β - and β -Klotho in urothelial carcinoma of the bladder. <i>Oncology Reports</i> , 2016, 36, 2117-2125.	2.6	20
39	Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients. <i>Cancer Science</i> , 2021, 112, 1524-1533.	3.9	19
40	Variations in health-related quality of life in Japanese men who underwent iodine-125 permanent brachytherapy for localized prostate cancer. <i>Brachytherapy</i> , 2010, 9, 300-306.	0.5	18
41	Risk-stratified survival rates and predictors of biochemical recurrence after radical prostatectomy in a Nara, Japan, cohort study. <i>International Journal of Clinical Oncology</i> , 2011, 16, 553-559.	2.2	18
42	Follow-up study of unilateral renal function after nephrectomy assessed by glomerular filtration rate per functional renal volume. <i>World Journal of Surgical Oncology</i> , 2014, 12, 59.	1.9	18
43	Estimated functional renal parenchymal volume predicts the split renal function following renal surgery. <i>World Journal of Urology</i> , 2015, 33, 1571-1577.	2.2	18
44	Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer. <i>BMC Cancer</i> , 2017, 17, 573.	2.6	18
45	Genitourinary toxicity after permanent iodine-125 seed implantation: The nationwide Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS). <i>Brachytherapy</i> , 2019, 18, 484-492.	0.5	18
46	Photodynamic diagnosis of shed prostate cancer cells in voided urine treated with 5-aminolevulinic acid. <i>BMC Urology</i> , 2014, 14, 59.	1.4	17
47	The Impact of Obstructive Sleep Apnea Syndrome on Nocturnal Urine Production in Older Men With Nocturia. <i>Urology</i> , 2014, 84, 892-897.	1.0	17
48	Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-1 blockade decreases local recurrence after surgery in bladder cancer. <i>Cancer Science</i> , 2019, 110, 3315-3327.	3.9	17
49	Low-dose-rate brachytherapy for prostate cancer: A 15-year experience in Japan. <i>International Journal of Urology</i> , 2020, 27, 17-23.	1.0	17
50	The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study. <i>BMC Research Notes</i> , 2016, 9, 79.	1.4	15
51	Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial. <i>BMC Cancer</i> , 2017, 17, 677.	2.6	15
52	Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute. <i>BMC Urology</i> , 2017, 17, 62.	1.4	15
53	Proposed salvage treatment strategy for biochemical failure after radical prostatectomy in patients with prostate cancer: a retrospective study. <i>Radiation Oncology</i> , 2014, 9, 208.	2.7	14
54	Spectrophotometric photodynamic detection involving extracorporeal treatment with hexaminolevulinate for bladder cancer cells in voided urine. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2309-2316.	2.5	14

#	ARTICLE	IF	CITATIONS
55	Transperineal template-guided saturation biopsy aimed at sampling one core for each milliliter of prostate volume: 103 cases requiring repeat prostate biopsy. <i>BMC Urology</i> , 2017, 17, 28.	1.4	14
56	Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitrosamine induced bladder cancer mouse model. <i>PLoS ONE</i> , 2017, 12, e0175494.	2.5	13
57	Disabled Homolog 2 (DAB2) Protein in Tumor Microenvironment Correlates with Aggressive Phenotype in Human Urothelial Carcinoma of the Bladder. <i>Diagnostics</i> , 2020, 10, 54.	2.6	13
58	A Genitourinary Cancer-specific Scoring System for the Prediction of Survival in Patients with Bone Metastasis: A Retrospective Analysis of Prostate Cancer, Renal Cell Carcinoma, and Urothelial Carcinoma. <i>Anticancer Research</i> , 2018, 38, 3097-3103.	1.1	13
59	Changes in lower urinary tract symptoms and quality of life after salvage radiotherapy for biochemical recurrence of prostate cancer. <i>Radiotherapy and Oncology</i> , 2015, 115, 321-326.	0.6	12
60	Extended resection including adjacent organs and Ki-67 labeling index are prognostic factors in patients with retroperitoneal soft tissue sarcomas. <i>World Journal of Surgical Oncology</i> , 2016, 14, 43.	1.9	12
61	Assessment of sexual function in Japanese men with prostate cancer undergoing permanent brachytherapy without androgen deprivation therapy: Analysis from the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation database. <i>International Journal of Urology</i> , 2017, 24, 518-524.	1.0	12
62	The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration: JMTO Pca 10-01 phase II trial. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 247-251.	1.3	12
63	Trends in risk classification and primary therapy of Japanese patients with prostate cancer in Nara urological research and treatment group (NURTG) – comparison between 2004–2006, 2007–2009, and 2010–2012. <i>BMC Cancer</i> , 2017, 17, 616.	2.6	12
64	Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer. <i>Clinical and Translational Radiation Oncology</i> , 2019, 14, 51-58.	1.7	12
65	Role of Nuclear Claudin-4 in Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8340.	4.1	12
66	Technical acquisition and dosimetric assessment of iodine-125 permanent brachytherapy in localized prostate cancer: Our first series of 100 patients. <i>International Journal of Urology</i> , 2009, 16, 70-74.	1.0	11
67	Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer. <i>BMC Urology</i> , 2012, 12, 28.	1.4	11
68	Urethral toxicity after LDR brachytherapy: Experience in Japan. <i>Brachytherapy</i> , 2015, 14, 131-135.	0.5	11
69	Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study). <i>Neurourology and Urodynamics</i> , 2017, 36, 1097-1103.	1.5	11
70	Aquaporin-2 plays an important role in water transportation through the bladder wall in rats. <i>Neurourology and Urodynamics</i> , 2018, 37, 2434-2440.	1.5	11
71	The impact of the definition of biochemical recurrence following salvage radiotherapy on outcomes and prognostication in patients with recurrent prostate cancer after radical prostatectomy: a comparative study of three definitions. <i>Prostate International</i> , 2019, 7, 47-53.	2.3	11
72	The primary therapy chosen for patients with localized prostate cancer between the university hospital and its affiliated hospitals in Nara Uro-oncological research group registration. <i>BMC Urology</i> , 2011, 11, 6.	1.4	10

#	ARTICLE	IF	CITATIONS
73	Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG)â€”a comparison between 2004-2006 and 2007-2009. <i>BMC Cancer</i> , 2013, 13, 588.	2.6	10
74	Insignificant role of bacillus Calmetteâ€”GuÃ©rin maintenance therapy after complete transurethral resection of bladder tumor for intermediateâ€”and highâ€”risk nonâ€”muscleâ€”invasive bladder cancer: Results from a randomized trial. <i>International Journal of Urology</i> , 2016, 23, 854-860.	1.0	10
75	Clinical utility of bioelectrical impedance analysis in patients with locoregional muscle invasive or metastatic urothelial carcinoma: a subanalysis of changes in body composition during neoadjuvant systemic chemotherapy. <i>Supportive Care in Cancer</i> , 2018, 26, 1077-1086.	2.2	10
76	Clinical Impact of the Increase in Immunosuppressive Cell-Related Gene Expression in Urine Sediment during Intravesical Bacillus Calmette-GuÃ©rin. <i>Diseases (Basel, Switzerland)</i> , 2019, 7, 44.	2.5	10
77	Evaluation of proâ€” and antiâ€”tumor effects induced by three colonyâ€”stimulating factors, Gâ€”CSF, GMâ€”CSF and Mâ€”CSF, in bladder cancer cells: Is Gâ€”CSF a friend of bladder cancer cells?. <i>International Journal of Oncology</i> , 2019, 54, 2237-2249.	3.3	10
78	Health utility and health-related quality of life of Japanese prostate cancer patients according to progression status measured using EQ-5D-5L and FACT-P. <i>Quality of Life Research</i> , 2019, 28, 2383-2391.	3.1	10
79	External validation of a genitourinary cancer-specific prognostic scoring system to predict survival for patients with bone metastasis (modified B-FOM scoring model): Comparison with other scoring models in terms of accuracy. <i>Journal of Bone Oncology</i> , 2021, 26, 100344.	2.4	10
80	Impact of Preoperative Abdominal Visceral Adipose Tissue Area and Nutritional Status on Renal Function After Donor Nephrectomy in Japanese Living Donors for Renal Transplantation. <i>Annals of Transplantation</i> , 2018, 23, 364-376.	0.9	10
81	5-Aminolevulinic acid overcomes hypoxia-induced radiation resistance by enhancing mitochondrial reactive oxygen species production in prostate cancer cells. <i>British Journal of Cancer</i> , 2022, 127, 350-363.	6.4	10
82	The optimal number of initial prostate biopsy cores in daily practice: a prospective study using the Nara Urological Research and Treatment Group nomogram. <i>BMC Research Notes</i> , 2015, 8, 689.	1.4	9
83	Clinical Significance of Tumor Size, Pathological Invasion Sites Including Urinary Collecting System and Clinically Detected Renal Vein Thrombus as Predictors for Recurrence in pT3a Localized Renal Cell Carcinoma. <i>Diagnostics</i> , 2020, 10, 154.	2.6	9
84	Photodynamic Diagnosis-Assisted En Bloc Transurethral Resection of Bladder Tumor for Nonmuscle Invasive Bladder Cancer: Short-Term Oncologic and Functional Outcomes. <i>Journal of Endourology</i> , 2021, 35, 319-327.	2.1	9
85	Integrative assessment of clinicopathological parameters and the expression of PDâ€”L1, PDâ€”L2 and PDâ€”1 in tumor cells of retroperitoneal sarcoma. <i>Oncology Letters</i> , 2020, 20, 1-1.	1.8	9
86	Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 196.e1-196.e9.	1.9	9
87	Improvement of the surgical curability of locally confined prostate cancer including non-organ-confined high-risk disease through retropubic radical prostatectomy with intentional wide resection. <i>World Journal of Surgical Oncology</i> , 2012, 10, 249.	1.9	8
88	Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus. <i>Oncology Reports</i> , 2017, 37, 227-234.	2.6	8
89	Atypical small acinar proliferation and two or more cores of high-grade intraepithelial neoplasia on a previous prostate biopsy are significant predictors of cancer during a transperineal template-guided saturation biopsy aimed at sampling one core for each 1 mL of prostate volume. <i>Research and Reports in Urology</i> , 2017, Volume 9, 187-193.	1.0	8
90	Comparison of chronological changes in urinary function in patients who underwent low-dose-rate brachytherapy for prostate cancerâ€”A randomized controlled trial of alpha-1 adrenoceptor antagonist alone versus combination with cyclooxygenase-2 inhibitorâ€”. <i>Brachytherapy</i> , 2018, 17, 537-543.	0.5	8

#	ARTICLE	IF	CITATIONS
91	Docetaxel-based chemotherapy combined with dexamethasone 1Âmg daily oral administration for castration-resistant prostate cancer: Long-term outcomes. <i>International Journal of Urology</i> , 2019, 26, 797-803.	1.0	8
92	Clinical benefit of early treatment with bone-modifying agents for preventing skeletal-related events in patients with genitourinary cancer with bone metastasis: A multi-institutional retrospective study. <i>International Journal of Urology</i> , 2019, 26, 630-637.	1.0	8
93	Quality of life in patients who underwent 125I brachytherapy, 125I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer. <i>Journal of Radiation Research</i> , 2019, 60, 270-280.	1.6	8
94	Inhibition of Heparanase Expression Results in Suppression of Invasion, Migration and Adhesion Abilities of Bladder Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3789.	4.1	8
95	Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer. <i>Cancer Science</i> , 2021, 112, 3616-3626.	3.9	8
96	Videourodynamic effects of vibegron, a new selective Î²3-adrenoceptor agonist, on antimuscarinic-resistant neurogenic bladder dysfunction in patients with spina bifida. <i>International Journal of Urology</i> , 2022, 29, 76-81.	1.0	8
97	Significant Improvement of Prognosis After the Advent of Immune Checkpoint Inhibitors in Patients with Advanced, Unresectable, or Metastatic Urothelial Carcinoma: A Propensity Score Matching and Inverse Probability of Treatment Weighting Analysis on Real-World Data. <i>Cancer Management and Research</i> , 2022, Volume 14, 623-635.	1.9	8
98	Calculated Tumor Volume Is an Independent Predictor of Biochemical Recurrence in Patients Who Underwent Retropubic Radical Prostatectomy. <i>Advances in Urology</i> , 2012, 2012, 1-7.	1.3	7
99	Increased Urine Production Due to Leg Fluid Displacement Reduces Hours of Undisturbed Sleep. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2018, 10, 253-258.	1.3	7
100	Overactive bladder induces transient hypertension. <i>BMC Research Notes</i> , 2018, 11, 196.	1.4	7
101	Urinary nerve growth factor can predict therapeutic efficacy in children with monosymptomatic nocturnal enuresis. <i>Neurourology and Urodynamics</i> , 2019, 38, 2311-2317.	1.5	7
102	Tadalafil, a phosphodiesterase type 5 inhibitor, restores urethra and detrusor function in the initial phase of diabetes in rats. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019, 11, 241-247.	1.3	7
103	Fluorescent cystoscopy-assisted en bloc transurethral resection versus conventional transurethral resection in patients with non-muscle invasive bladder cancer: study protocol of a prospective, open-label, randomized control trial (the FLEBER study). <i>Trials</i> , 2021, 22, 136.	1.6	7
104	Hexylaminolevulinatemediated fluorescent urine cytology with a novel automated detection technology for screening and surveillance of bladder cancer. <i>BJU International</i> , 2021, 128, 244-253.	2.5	7
105	Long-term Changes in Renal Function, Blood Electrolyte Levels, and Nutritional Indices after Radical Cystectomy and Ileal Conduit in Patients with Bladder Cancer. <i>Urology Journal</i> , 2019, 16, 145-151.	0.4	7
106	A Randomized Control Trial Comparing the Efficacy of Antiandrogen Monotherapy: Flutamide vs. Bicalutamide. <i>Hormones and Cancer</i> , 2015, 6, 161-167.	4.9	6
107	Cognitive burden and polypharmacy in elderly Japanese patients treated with anticholinergics for an overactive bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2020, 12, 54-61.	1.3	6
108	Initial experience of complete laparoscopic radical nephroureterectomy combined with transvesical laparoscopic excision of distal ureter in patients with upper urinary tract cancer. <i>World Journal of Surgical Oncology</i> , 2020, 18, 104.	1.9	6

#	ARTICLE	IF	CITATIONS
109	The sustaining of fluorescence in photodynamic diagnosis after the administration of 5-aminolevulinic acid in carcinogen-induced bladder cancer orthotopic rat model and urothelial cancer cell lines. <i>Photodiagnosis and Photodynamic Therapy</i> , 2021, 34, 102309.	2.6	6
110	β-Klotho is correlated with resistance to docetaxel in castration-resistant prostate cancer. <i>Oncology Letters</i> , 2020, 19, 2306-2316.	1.8	6
111	Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study. <i>Cancers</i> , 2022, 14, 1735.	3.7	6
112	Unexpected presentation of allograft dysfunction triggered by pape kidney phenomenon immediately after kidney transplantation: a case report. <i>BMC Nephrology</i> , 2018, 19, 59.	1.8	5
113	Spectrophotometric photodynamic diagnosis of prostate cancer cells excreted in voided urine using 5-aminolevulinic acid. <i>Lasers in Medical Science</i> , 2018, 33, 1557-1563.	2.1	5
114	Comparison of cancer detection rates by transrectal prostate biopsy for prostate cancer using two different nomograms based on patient's age and prostate volume. <i>Research and Reports in Urology</i> , 2019, Volume 11, 61-68.	1.0	5
115	Prognostic impact of tumor-infiltrating CD276/Foxp3-positive lymphocytes and associated circulating cytokines in patients undergoing radical nephrectomy for localized renal cell carcinoma. <i>Oncology Letters</i> , 2019, 17, 4004-4010.	1.8	5
116	Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancer. <i>Journal of Contemporary Brachytherapy</i> , 2019, 11, 409-416.	0.9	5
117	Trends in treatment outcomes for retractile testis in Japanese boys: A single-center study. <i>International Journal of Urology</i> , 2021, 28, 327-332.	1.0	5
118	Effect of Prolonged Duration of Transrectal Ultrasound-Guided Biopsy of the Prostate and Pre-Procedure Anxiety on Pain in Patients without Anesthesia. <i>Research and Reports in Urology</i> , 2021, Volume 13, 111-120.	1.0	5
119	Clinical outcomes after intravesical bacillus Calmette-Guérin for the highest-risk non-muscle-invasive bladder cancer newly defined in the Japanese Urological Association Guidelines 2019. <i>International Journal of Urology</i> , 2021, 28, 720-726.	1.0	5
120	Trends in risk classification at diagnosis and choice of primary therapy for prostate cancer: An analysis of 10,839 patients from the Nara Urological Research and Treatment Group registry between 2004 and 2015. <i>International Journal of Urology</i> , 2021, 28, 1164-1170.	1.0	5
121	Remnant renal volume can predict prognosis of remnant renal function in kidney transplantation donors: a prospective observational study. <i>BMC Nephrology</i> , 2021, 22, 367.	1.8	5
122	Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for T1c prostate cancer. <i>Acta Urologica Japonica</i> , 2007, 53, 459-65.	0.1	5
123	Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer. <i>Radiation Oncology</i> , 2022, 17, 71.	2.7	5
124	Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy. <i>BMC Cancer</i> , 2015, 15, 420.	2.6	4
125	Successful salvage of allograft dysfunction triggered by transplant renal vein thrombosis immediately after kidney transplantation: a case report. <i>International Journal of Nephrology and Renovascular Disease</i> , 2018, Volume 11, 321-327.	1.8	4
126	Colony-stimulating factors detected in tumor cells and voided urine are potential prognostic markers for patients with muscle-invasive bladder cancer undergoing radical cystectomy. <i>Research and Reports in Urology</i> , 2018, Volume 10, 103-111.	1.0	4

#	ARTICLE	IF	CITATIONS
127	Clinical Significance of Postoperative Nutritional Status as a Prognostic Factor in Kidney Transplant Recipients. <i>Transplantation Proceedings</i> , 2019, 51, 1763-1772.	0.6	4
128	A Potential Application of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Combined with Photodynamic Diagnosis for the Detection of Bladder Carcinoma in Situ: Toward the Future "MRI-PDD Fusion TURBT". <i>Diagnostics</i> , 2019, 9, 112.	2.6	4
129	Evaluation of Preoperative Abdominal Adipose Tissue, Inflammation-, Muscle Mass, and Nutritional Status-based Prognostic Markers to Assess Renal Dysfunction in Living Kidney Donors. <i>Transplantation Proceedings</i> , 2019, 51, 1706-1716.	0.6	4
130	Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette-Guerin by the modulation of the tumor immune environment. <i>Oncology Reports</i> , 2019, 41, 1863-1874.	2.6	4
131	The diagnostic utility of retroperitoneoscopic tissue biopsy for unresectable retroperitoneal lesions excluding urogenital cancers. <i>World Journal of Surgical Oncology</i> , 2019, 17, 35.	1.9	4
132	Intravesical Bacillus Calmette-Guerin treatment-induced sleep quality deterioration in patients with non-muscle invasive bladder cancer: functional outcome assessment based on a questionnaire survey and actigraphy. <i>Supportive Care in Cancer</i> , 2022, 30, 887-895.	2.2	4
133	Usefulness of clinical factors for diagnosing and differentiating types of testicular malposition in boys: A retrospective study. <i>International Journal of Urology</i> , 2022, 29, 57-64.	1.0	4
134	Comparative effectiveness of low-dose-rate brachytherapy with or without external beam radiotherapy in favorable and unfavorable intermediate-risk prostate cancer. <i>Scientific Reports</i> , 2022, 12, .	3.3	4
135	Characteristics and management of erectile dysfunction after various treatments for prostate cancer. <i>International Journal of Urology</i> , 2010, 17, 689-697.	1.0	3
136	Prostate-specific antigen bounce after 125I-brachytherapy for prostate cancer is a favorable prognosticator in patients who are biochemical recurrence-free at 4 years and correlates with testosterone. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 58-65.	1.3	3
137	Daily salt intake is associated with leg edema and nocturnal urinary volume in elderly men. <i>Neurourology and Urodynamics</i> , 2020, 39, 1550-1556.	1.5	3
138	A prospective, single-arm trial of fluorescent ureteroscopy-assisted thulium-holmium:YAG dual laser ablation for upper urinary tract cancer: Study protocol of the FLUAM trial. <i>Contemporary Clinical Trials Communications</i> , 2022, 26, 100902.	1.1	3
139	Salvage brachytherapy for seminal vesicle recurrence after initial brachytherapy for prostate cancer: a case report. <i>BMC Research Notes</i> , 2014, 7, 760.	1.4	2
140	Oncological outcome, complications, lower urinary tract symptoms, and health-related quality of life after low-dose-rate salvage brachytherapy for recurrent prostate cancer following primary radiotherapy: a report of 8 cases. <i>Journal of Contemporary Brachytherapy</i> , 2017, 4, 364-372.	0.9	2
141	Quality of life worsened the most severely in patients immediately after intensity-modulated radiation therapy for prostate cancer. <i>Research and Reports in Urology</i> , 2018, Volume 10, 169-180.	1.0	2
142	Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide. <i>BMC Research Notes</i> , 2018, 11, 342.	1.4	2
143	Amrubicin is effective against small cell carcinoma of the prostate as a second-line chemotherapeutic agent: A case report. <i>IJU Case Reports</i> , 2019, 2, 133-136.	0.3	2
144	Factors contributing to the ceiling effect of the EQ-5D-5L: an analysis of patients with prostate cancer judged "no-problems". <i>Quality of Life Research</i> , 2020, 29, 755-763.	3.1	2

#	ARTICLE	IF	CITATIONS
145	Biochemical control of the combination of cyclooxygenase-2 inhibitor and 125 I-Brachytherapy for prostate cancer: Post hoc analysis of an open-label controlled randomized trial. <i>International Journal of Urology</i> , 2020, 27, 755-759.	1.0	2
146	Trends in treatment outcomes of hydrocele in Japanese children: A single-institute experience. <i>International Journal of Urology</i> , 2020, 27, 946-950.	1.0	2
147	Coverage of the external prostatic region by the hybrid method compared with the conventional method of prostate low-dose-rate brachytherapy: A randomized controlled study. <i>International Journal of Urology</i> , 2020, 27, 1013-1017.	1.0	2
148	Living-donor kidney transplantation for a patient with hypoparathyroidism, deafness, and renal dysplasia syndrome. <i>IJU Case Reports</i> , 2020, 3, 244-247.	0.3	2
149	Sodium plays an important role in the absorption of intravesical fluid. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2021, 13, 177-182.	1.3	2
150	Appropriate Number of Docetaxel Cycles in Castration-Resistant Prostate Cancer Patients Considering Peripheral Neuropathy and Oncological Control. <i>Chemotherapy</i> , 2020, 65, 1-6.	1.6	2
151	Non-ischemic, Non-renalorrhaphy Laparoscopic Partial Nephrectomy Using a Microwave Tissue Coagulator for Small Renal Tumors. <i>Journal of Microwave Surgery</i> , 2016, 34, 1-6.	0.3	2
152	Inhibitory Effect of Orally Administered 5-Aminolevulinic Acid on Prostate Carcinogenesis in the FVB-Transgenic Adenocarcinoma of a Mouse Prostate (FVB-TRAMP) Model. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 3743-3749.	1.2	2
153	Impact of neoadjuvant androgen deprivation therapy on postimplant prostate D90 and prostate volume after low-dose-rate brachytherapy for localized prostate cancer. <i>International Journal of Urology</i> , 2021, , .	1.0	2
154	Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma. <i>IJU Case Reports</i> , 0, , .	0.3	2
155	Localized prostate cancer with pelvic arteriovenous malformation treated with low-dose-rate brachytherapy after transcatheter embolization: Two case reports. <i>IJU Case Reports</i> , 2019, 2, 90-94.	0.3	1
156	Evaluating the optimal technique of transperineal template-guided saturation biopsy in patients requiring repeat prostate biopsy. <i>International Journal of Urology</i> , 2020, 27, 1157-1158.	1.0	1
157	A prospective study of oral 5-aminolevulinic acid to prevent adverse events in patients with localized prostate cancer undergoing low-dose-rate brachytherapy: Protocol of the AMBER study. <i>Contemporary Clinical Trials Communications</i> , 2020, 19, 100593.	1.1	1
158	Impact of Radical Nephrectomy and Partial Nephrectomy on Actual Estimated Overall Survival Compared to Life Expectancy in Patients with Renal Cell Carcinoma. <i>Research and Reports in Urology</i> , 2021, Volume 13, 155-165.	1.0	1
159	Factors affecting urinary frequency after low-dose-rate brachytherapy for prostate cancer. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2021, , .	1.3	1
160	Comparison of disease-specific quality of life in prostate cancer patients treated with low-dose-rate brachytherapy: A randomized controlled trial of silodosin versus naftopidil. <i>International Journal of Urology</i> , 2021, 28, 1171-1176.	1.0	1
161	Assessment of bladder function for stabilizing urinary volume overnight with recording of brain waves (ABSORB study). <i>LUTS: Lower Urinary Tract Symptoms</i> , 2021, , .	1.3	1
162	Erectile dysfunction and sexual quality of life in patients who underwent low-dose-rate brachytherapy alone for prostate cancer. <i>Andrologia</i> , 2022, 54, e14288.	2.1	1

#	ARTICLE	IF	CITATIONS
163	Clinical Impact of Subclinical Interstitial Fibrosis or Tubular Atrophy in 1-Hour Allograft Biopsy for Remnant Renal Function in Living Kidney Donors: A Prospective Observational Study. <i>Transplantation Proceedings</i> , 2021, 53, 2833-2840.	0.6	1
164	Relevance of the perioperative edema index measured by bioelectrical impedance analysis for prediction of cardiovascular disease in living donor kidney transplantation. <i>International Journal of Urology</i> , 2022, , .	1.0	1
165	Mirabegron Reduces Urinary Frequency and Improves Overactive Bladder Symptoms at 3 Months After 125I-brachytherapy for Prostate Cancer: An Open-Labelled, Randomized, Non-Placebo-Controlled Study. <i>Urology</i> , 2022, 161, 87-92.	1.0	1
166	Comparison of serum levels of pyridinoline and pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen as markers of bone resorption in patients receiving maintenance hemodialysis. <i>Clinical and Experimental Nephrology</i> , 1998, 2, 64-71.	1.6	0
167	Rationale, design, and methods of electroencephalography-based investigation of the effects of oral desmopressin on improving slow-wave sleep time in nocturnal polyuria patients (the DISTINCT study): protocol for a single-arm, open-label, single-assignment trial. <i>BMC Urology</i> , 2020, 20, 96.	1.4	0
168	Is Endoscopic Transurethral Incision Really Effective for Boys with Refractory Daytime Incontinence?. <i>Research and Reports in Urology</i> , 2020, Volume 12, 273-277.	1.0	0
169	Long-term chronological changes in renal function and functional renal volume after nephron-sparing surgery: A prospective observational study. <i>International Journal of Urology</i> , 2021, 28, 1112-1119.	1.0	0
170	The surgical outcomes of non-ischemic partial nephrectomy using a microwave tissue coagulator for stage T1 renal cell carcinoma. <i>Journal of Microwave Surgery</i> , 2010, 28, 69-74.	0.3	0
171	A peritoneal dialysis patient with a right-sided aortic arch died of bronchial obstruction due to the enlargement of a Kommerell's diverticulum after laparoscopic nephrectomy for renal cell carcinoma. <i>Nihon Toseki Igakkai Zasshi</i> , 2016, 49, 247-252.	0.1	0
172	A case in which colonic perforation occurred twice 10 years after cadaveric kidney transplantation. <i>Nihon Toseki Igakkai Zasshi</i> , 2019, 52, 551-557.	0.1	0
173	Editorial Comment on Ischemic proctitis after low-dose-rate brachytherapy using hydrogel spacer for prostate cancer. <i>IJU Case Reports</i> , 2022, 5, 241-241.	0.3	0
174	Association between urine 6-sulfatoxy-melatonin level and intravesical Bacillus Calmette-Guerin treatment-induced sleep quality deterioration in patients with non-muscle invasive bladder cancer. <i>Supportive Care in Cancer</i> , 2022, , 1.	2.2	0
175	Late genitourinary and gastrointestinal toxicity and radiation-induced second primary cancers in patients treated with low-dose-rate brachytherapy. <i>Brachytherapy</i> , 2022, , .	0.5	0
176	Efficacy of medical expulsive therapy using the traditional Japanese medicine (kampo) choreito for the spontaneous passage of proximal ureteric stones: A retrospective analysis. <i>Traditional & Kampo Medicine</i> , 0, , .	0.6	0
177	Clinical impact of perioperative body fluid management in kidney transplant recipients. <i>Nihon Toseki Igakkai Zasshi</i> , 2022, 55, 379-385.	0.1	0